Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $60.17 USD
Change Today -0.334 / -0.55%
Volume 128.6K
CYBX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 12:19 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

cyberonics inc (CYBX) Snapshot

Open
$60.97
Previous Close
$60.50
Day High
$60.97
Day Low
$59.72
52 Week High
02/26/15 - $76.48
52 Week Low
11/20/14 - $48.19
Market Cap
1.6B
Average Volume 10 Days
205.0K
EPS TTM
$2.41
Shares Outstanding
26.0M
EX-Date
--
P/E TM
24.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for CYBERONICS INC (CYBX)

cyberonics inc (CYBX) Related Bloomberg News

View More Bloomberg News

cyberonics inc (CYBX) Related Businessweek News

No Related Businessweek News Found

cyberonics inc (CYBX) Details

Cyberonics, Inc., together with its subsidiaries, designs, develops, markets, and sells medical devices to hospitals and ambulatory surgery centers. It offers vagus nerve stimulation therapy system, an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression; and VITARIA System, an implantable device that offers a form of neuromodulation therapy for the treatment of chronic heart failure. The company is also developing non-implantable device solutions for the management of epilepsy. It sells its products directly, as well as through independent distributors in the United States and internationally. Cyberonics, Inc. was founded in 1987 and is headquartered in Houston, Texas.

660 Employees
Last Reported Date: 06/15/15
Founded in 1987

cyberonics inc (CYBX) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $613.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $334.1K
Chief Operating Officer
Total Annual Compensation: $186.6K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $318.1K
Vice President of Emerging Therapy
Total Annual Compensation: $100.4K
Compensation as of Fiscal Year 2014.

cyberonics inc (CYBX) Key Developments

Sorin S.p.A. and Cyberonics, Inc. Announces Management Appointments for the Combined Company

Sorin S.p.A. and Cyberonics Inc. have named their respective designees to the board of directors of the combined company effective at the close of their proposed merger. Under the terms of the merger agreement entered into by Cyberonics and Sorin, the board of directors of the combined company will be comprised of nine members, four of whom are to be designated by Sorin and four of whom are to be designated by Cyberonics. Dan Moore, Cyberonics' current chief executive officer, will be the non-executive chairman of the board of directors of the combined company. Andr©-Michel Ballester, Sorin's chief executive officer, will serve as the combined company's chief executive officer and a member of its board of directors. In addition to Moore and Ballester, the board of directors will be comprised of Rosario Bifulco, Sorin's current chairman, Hugh Morrison, Cyberonics' current chairman, Alfred J. Novak, a member of Cyberonics' audit and nominating and governance committees, Arthur L. Rosenthal, chairman of Cyberonics' compensation committee and a member of its audit committee, Massimo Tononi, a member of Sorin's current board of directors and Francesco Bianchi, a former member of Sorin's board. Sorin and Cyberonics have initiated a search for the ninth director of the combined company, to be jointly designated by them. Until the closing of the transaction, the respective companies will continue to operate under their current leadership structures and as two separate companies. The transaction is expected to be completed by the end of third quarter of 15 and is subject to approval by Cyberonics's stockholders, the receipt of required regulatory clearances, and other customary closing conditions.

Cyberonics Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended April 24, 2015; Provides Earnings Guidance for the Fiscal Year 2016; Reports Asset Impairments for the Fourth Quarter Ended April 24, 2015

Cyberonics Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended April 24, 2015. For the quarter, the company reported net sales of $74,071,606 compared with $74,849,270 for the same period last year. Income from operations was $16,720,359 compared with $23,418,020 for the same period last year. Income before income taxes was $16,863,660 compared with $23,363,352 for the same period last year. Net income was $10,514,062 or $0.40 diluted per share compared with $18,428,006 or $0.68 diluted per share for the same period last year. Adjusted non-GAAP net income was $16,944,753 or $0.64 diluted per share compared with $14,894,331 or $0.55 diluted per share for the same period last year. Adjusted EBITDA was $31,769,805 compared with $27,718,303 for the same period last year. Adjusted non-GAAP income from operations was $23,418,020 against $20,463,569 a year ago. Adjusted non-GAAP income from operations was $26,494,900 against $23,418,020 a year ago. Adjusted non-GAAP net sales were $74,071,606 against $72,203,270 a year ago. For the year, the company reported net sales of $291,557,998 compared with $282,014,160 for the same period last year. Income from operations was $88,651,718 compared with $80,011,750 for the same period last year. Income before income taxes was $89,294,077 compared with $79,878,696 for the same period last year. Net income was $57,847,534 or $2.17 diluted per share compared with $54,890,257 or $2.00 diluted per share for the same period last year. Adjusted non-GAAP net income was $64,852,989 or $2.44 diluted per share compared with $55,211,788 or $2.01 diluted per share for the same period last year. Adjusted EBITDA was $118,668,558 compared with $102,829,208 for the same period last year. Adjusted non-GAAP income from operations was $99,474,095 against $85,986,728 a year ago. Net cash provided by operating activities was $79,675,116 against $54,195,816 a year ago. Purchases of property, plant and equipment was $6,686,589 against $15,222,440 a year ago. Adjusted non-GAAP net sales were $291,557,998 against $275,800,291 a year ago. For the fourth quarter, the company reported asset impairments of $1,807,096. For fiscal 2016, the company expects sales growth rates will be higher than in the recently completed fiscal year and more in line with historical averages. The company expects a lower gross margin in fiscal 2016.

Cyberonics Inc. Announces FDA Approval of AspireSR® Generator for VNS Therapy®

Cyberonics Inc. announced FDA approval of the AspireSR® generator for the VNS Therapy® System – the first and only VNS Therapy System that provides responsive stimulation to heart-rate increases that are often associated with seizures in people with epilepsy. Studies have shown that 82% of patients with epilepsy experience rapid heart-rate increase associated with a seizure. The AspireSR generator uses a proprietary, patent protected, customizable cardiac-based algorithm to detect relative heart-rate increases and deliver automatic stimulation. Drug-Resistant Epilepsy and VNS Therapy: Epilepsy is the fourth most common neurological disorder and one in 26 people will develop epilepsy at some point in their lifetime. Seizure medications are typically the first option for treating epilepsy. While many people with epilepsy have success with these drugs, as many as one-third of people with epilepsy experience seizures that persist in spite of treatment with medications alone. The VNS Therapy System is an FDA-approved medical device specifically developed for the adjunctive treatment of drug-resistant (medically refractory) epilepsy. Treatment with the VNS Therapy System does not involve brain surgery, but rather the medical device – implanted in a simple, out-patient procedure under the skin of the chest – delivers mild, pulsed electrical signals to the vagus nerve, which project to areas of the brain that are known to be implicated in seizures. Studies show that a majority of people with drug-resistant epilepsy experience a 50% to 90% reduction in seizures with the VNS Therapy System and report improvements in quality of-life.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYBX:US $60.17 USD -0.334

CYBX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.40 USD -0.23
ICU Medical Inc $98.20 USD +0.21
Orthofix International NV $33.30 USD +0.07
RTI Surgical Inc $6.74 USD +0.09
Wright Medical Group Inc $25.85 USD -0.23
View Industry Companies
 

Industry Analysis

CYBX

Industry Average

Valuation CYBX Industry Range
Price/Earnings 28.2x
Price/Sales 5.5x
Price/Book 5.7x
Price/Cash Flow 27.5x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYBERONICS INC, please visit www.cyberonics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.